Specialised Therapeutics

Singapore-based Specialised Therapeutics Asia Pte Ltd (ST) has been appointed to handle the commercialization of the programmed death-1 (PD-1) inhibitor, Anniko (penpulimab), in Australia, Singapore, and South-East Asia. The drug is developed by the joint venture (JV) CTTQ-Akeso (Shanghai) Biomed Tech Co., Ltd, a partnership between Akeso Inc. (HKG: 9926)…